Antifungal activity of GBR-14206, a new imidazole derivative: In vitro studies.:In Vitro Studies
スポンサーリンク
概要
- 論文の詳細を見る
The antifungal activity of GBR-14206, a new imidazole derivative, was evaluated in comparison with those of clotrimazole (CTZ) and miconazole (MCZ) using an agar dilution procedure.GBR-14206 showed a potent activity against a wide range of pathogenic fungi including those associated with deep-seated and subcutaneous mycosis; it inhibited some standard strains of C. albicans at concentrations of 12.5μg/ml or less. Similarly, clinical isolates from various mycoses were also highly susceptible to GBR-14206 (MIC range; 0.0125-6.25μg/ml). The most striking activity of GBR-14206 was displayed against Cryptococcus neoformans (MIC range; 0.0125-0.05μg/ml), which was far superior to MCZ and CTZ. Against C. albicans, Trichophyton spp., and Microsporum spp., the activity of GBR-14206 was more moderate than MCZ and CTZ. Against Sporothrix schenckii, GBR-14206 had a lower mean MIC value than that of CTZ and was similar to MCZ. On the other hand, against Aspergillus spp., GBR-14206 was less effective than MCZ and CTZ. Fungal susceptibility of GBR-14206 tended to be enhanced with increasing medium pH. The activity was also lowered by addition of calf serum.
- 日本医真菌学会の論文
日本医真菌学会 | 論文
- (1→3)-β-D-グルカン測定の問題点と進歩
- 両側の肺空洞病変にアスペルギルス感染を合併し抗真菌薬, ミカファンギンとイトラコナゾールの併用療法が有効であった Wegener 肉芽腫症の一例
- Trichophyton tonsurans 臨床分離株に対する各種抗真菌薬の in vitro 抗真菌活性
- 爪白癬の治療について : 日本医真菌学会標準化委員会提案2007
- Candida 属菌種のアゾール系薬感受性試験における現行の日本医真菌学会法, およびその改変法とNCCLS M27-A2法との相関性に関する検討